Insider · CIK 0001653881
Robert C. Goeltz II
Files at RCUS (Arcus Biosciences, Inc.). First filing Jan 4, 2024, latest May 12, 2026.
In brief
Robert C. Goeltz II files SEC Form 4 as CFO at RCUS (Arcus Biosciences, Inc.). Since Jan 4, 2024, Robert C. Goeltz II has reported 0 open-market buys worth $0 and 7 open-market sells worth $950k, the latest filed on May 12, 2026.
A track record needs three past buys with six months of prices behind them; Robert C. Goeltz II has 0, so none is measured yet.
The newest scored trade: sold $199k of RCUS on May 11, 2026, filed May 12, 2026, scored 14 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $856k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RCUS: Arcus Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Arcus Biosciences, Inc. | $199k 7,763 shares | -8% | +213% from low-7% from high | |
| 21Weak | Arcus Biosciences, Inc. | $153k 6,552 shares | -9% | +247% from low-9% from high | |
| 36Weak | Arcus Biosciences, Inc. | $279k 12,662 shares | -15% | +223% from low-15% from high | |
| 27Weak | Arcus Biosciences, Inc. | $125k 5,000 shares | -5% | +272% from low0% from high | |
| 27Weak | Arcus Biosciences, Inc. | $100k 5,000 shares | -5% | +189% from low0% from high | |
| 9Weak | Arcus Biosciences, Inc. | $54k 3,594 shares | -6% | - | |
| 23Weak | Arcus Biosciences, Inc. | $40k 2,004 shares | -4% | +47% from low-16% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 11, 2026 | RCUS Arcus Biosciences, Inc. | 7,763 0.01% of outstanding | $199k | May 11, 2026 | none |
| Dec 31, 2025 | RCUS Arcus Biosciences, Inc. | 6,552 0.01% of outstanding | $153k | Dec 31, 2025 | $504k |
| Dec 15, 2025 | RCUS Arcus Biosciences, Inc. | 14,000 0.01% of outstanding | $307k | Dec 16, 2025 | $225k |
| Nov 26, 2025 | RCUS Arcus Biosciences, Inc. | 5,000 0.00% of outstanding | $125k | Nov 26, 2025 | $100k |
| Oct 28, 2025 | RCUS Arcus Biosciences, Inc. | 5,000 0.00% of outstanding | $100k | Oct 28, 2025 | none |
| Dec 31, 2024 | RCUS Arcus Biosciences, Inc. | 3,594 0.00% of outstanding | $54k | Dec 31, 2024 | none |
| Jan 2, 2024 | RCUS Arcus Biosciences, Inc. | 2,004 0.00% of outstanding | $40k | Jan 2, 2024 | $100k |
| Dec 15, 2023 | RCUS Arcus Biosciences, Inc. | 5,500 0.01% of outstanding | $96k | Dec 18, 2023 | none |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -7,763 | $25.63 | $199k | 84,161 | May 12, 2026 |
| Jan 23, 2026 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 91,924 | Jan 26, 2026 |
| Jan 23, 2026 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +96,000 | $0.00 | $0 | 96,000 | Jan 26, 2026 |
| Dec 31, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -6,552 | $23.38 | $153k | 67,924 | Jan 2, 2026 |
| Dec 16, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -6,702 | $21.88 | $147k | 80,436 | Dec 18, 2025 |
| Dec 17, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -5,960 | $22.16 | $132k | 74,476 | Dec 18, 2025 |
| Nov 26, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $25.00 | $125k | 87,138 | Nov 26, 2025 |
| Oct 28, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $20.00 | $100k | 92,138 | Oct 29, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +37,000 | $0.00 | $0 | 97,138 | Jan 27, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 27, 2025 |
| Dec 31, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -3,594 | $15.00 | $54k | 60,138 | Jan 3, 2025 |
| Dec 15, 2024 | RCUS Arcus Biosciences, Inc. | FTax withholding Common Stock | -10,099 | $16.08 | $162k | 63,732 | Dec 17, 2024 |
| Jan 23, 2024 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +21,300 | $0.00 | $0 | 73,131 | Jan 25, 2024 |
| Jan 23, 2024 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +86,600 | $0.00 | $0 | 86,600 | Jan 25, 2024 |
| Jan 2, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,004 | $20.00 | $40k | 51,831 | Jan 4, 2024 |
| Dec 18, 2023 | RCUS Arcus Biosciences, Inc. | DDisposition to issuer Common Stock10b5-1 | -2,749 | $17.74 | $49k | 56,643 | Dec 20, 2023 |
| Dec 19, 2023 | RCUS Arcus Biosciences, Inc. | DDisposition to issuer Common Stock10b5-1 | -2,808 | $18.09 | $51k | 53,835 | Dec 20, 2023 |
Questions about Robert C. Goeltz II
Answered from the filings on this page, as of the latest one.
Is Robert C. Goeltz II buying or selling?
In the last 12 months Robert C. Goeltz II reported 0 open-market buys worth $0 and 5 open-market sells worth $856k on SEC Form 4; the latest was sold $199k of RCUS on May 11, 2026. Grants, option exercises and tax withholding are not counted.
How did Robert C. Goeltz II's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert C. Goeltz II has 0.
Where does Robert C. Goeltz II file Form 4?
Robert C. Goeltz II has filed Form 4 at RCUS (Arcus Biosciences, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.